The Pathogenesis of the Bone Disease of Multiple Myeloma

Overview

Journal Bone

Specialties Endocrinology
Orthopedics

Date 2008 Apr 15

PMID 18406675

Citations 76

Authors

Claire M Edwards

Junling Zhuang

Gregory R Mundy

Affiliations

Soon will be listed here.

Abstract

Multiple myeloma is a fatal hematologic malignancy associated with clonal expansion of malignant plasma cells within the bone marrow and the development of a destructive osteolytic bone disease. The principal cellular mechanisms involved in the development of myeloma bone disease are an increase in osteoclastic bone resorption, and a reduction in bone formation. Myeloma cells are found in close association with sites of active bone resorption, and the interactions between myeloma cells and other cells within the specialized bone marrow microenvironment are essential, both for tumor growth and the development of myeloma bone disease. This review discusses the many different factors which have been implicated in myeloma bone disease, including the evidence for their role in myeloma and subsequent therapeutic implications.

Citing Articles

Multiple Myeloma Insights from Single-Cell Analysis: Clonal Evolution, the Microenvironment, Therapy Evasion, and Clinical Implications.

Li S, Liu J, Peyton M, Lazaro O, McCabe S, Huang X Cancers (Basel). 2025; 17(4).

PMID: 40002248 PMC: 11852428. DOI: 10.3390/cancers17040653.

New horizons in our understanding of precursor multiple myeloma and early interception.

Cordas Dos Santos D, Toenges R, Bertamini L, Alberge J, Ghobrial I Nat Rev Cancer. 2024; 24(12):867-886.

PMID: 39414947 DOI: 10.1038/s41568-024-00755-x.

Cellular taxonomy of the preleukemic bone marrow niche of acute myeloid leukemia.

Goda C, Kulkarni R, Bustos Y, Li W, Rudich A, Balcioglu O Leukemia. 2024; 39(1):51-63.

PMID: 39358541 PMC: 11717697. DOI: 10.1038/s41375-024-02415-3.

Descriptive Analysis of Adverse Events Reported for New Multiple Myeloma Medications Using FDA Adverse Event Reporting System (FAERS) Databases from 2015 to 2022.

Alrasheed M, Alamer K, Albishi M, Alsuhibani A, Almohammed O, Alwhaibi A Pharmaceuticals (Basel). 2024; 17(7).

PMID: 39065666 PMC: 11279559. DOI: 10.3390/ph17070815.

TGF-β: an active participant in the immune and metabolic microenvironment of multiple myeloma : TGF-β in the microenvironment of multiple myeloma.

Xue H, Wei F Ann Hematol. 2024; 103(11):4351-4362.

PMID: 38900304 PMC: 11534828. DOI: 10.1007/s00277-024-05843-4.

References

Terpos E, Politou M, Szydlo R, Goldman J, Apperley J, Rahemtulla A . Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma. Br J Haematol. 2003; 123(1):106-9. DOI: 10.1046/j.1365-2141.2003.04561.x. View

Mundy G . Myeloma bone disease. Eur J Cancer. 1998; 34(2):246-51. DOI: 10.1016/s0959-8049(97)10133-2. View

Giuliani N, Colla S, Morandi F, Lazzaretti M, Sala R, Bonomini S . Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood. 2005; 106(7):2472-83. DOI: 10.1182/blood-2004-12-4986. View

Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S . Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood. 2001; 98(13):3527-33. DOI: 10.1182/blood.v98.13.3527. View

Gong Y, Slee R, Fukai N, Rawadi G, Roman-Roman S, Reginato A . LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell. 2001; 107(4):513-23. DOI: 10.1016/s0092-8674(01)00571-2. View

Yu X, Huang Y, Collin-Osdoby P, Osdoby P . Stromal cell-derived factor-1 (SDF-1) recruits osteoclast precursors by inducing chemotaxis, matrix metalloproteinase-9 (MMP-9) activity, and collagen transmigration. J Bone Miner Res. 2003; 18(8):1404-18. DOI: 10.1359/jbmr.2003.18.8.1404. View

Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K . Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature. 1988; 332(6159):83-5. DOI: 10.1038/332083a0. View

Giuliani N, Morandi F, Tagliaferri S, Lazzaretti M, Bonomini S, Crugnola M . The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood. 2007; 110(1):334-8. DOI: 10.1182/blood-2006-11-059188. View

Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B . The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003; 349(26):2483-94. DOI: 10.1056/NEJMoa030847. View

10.

Bataille R, Chappard D, Marcelli C, Dessauw P, Baldet P, Sany J . Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest. 1991; 88(1):62-6. PMC: 296003. DOI: 10.1172/JCI115305. View

11.

Richardson P, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D . Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood. 2005; 106(9):2977-81. DOI: 10.1182/blood-2005-02-0691. View

12.

Ehrlich L, Chung H, Ghobrial I, Choi S, Morandi F, Colla S . IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood. 2005; 106(4):1407-14. DOI: 10.1182/blood-2005-03-1080. View

13.

Gunn W, Conley A, Deininger L, Olson S, Prockop D, Gregory C . A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells. 2005; 24(4):986-91. DOI: 10.1634/stemcells.2005-0220. View

14.

Bataille R, Delmas P, Chappard D, Sany J . Abnormal serum bone Gla protein levels in multiple myeloma. Crucial role of bone formation and prognostic implications. Cancer. 1990; 66(1):167-72. DOI: 10.1002/1097-0142(19900701)66:1<167::aid-cncr2820660130>3.0.co;2-9. View

15.

Kong Y, Yoshida H, Sarosi I, Tan H, Timms E, Capparelli C . OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999; 397(6717):315-23. DOI: 10.1038/16852. View

16.

Simonet W, Lacey D, Dunstan C, Kelley M, Chang M, Luthy R . Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997; 89(2):309-19. DOI: 10.1016/s0092-8674(00)80209-3. View

17.

Woitge H, Horn E, Keck A, Auler B, Seibel M, Pecherstorfer M . Biochemical markers of bone formation in patients with plasma cell dyscrasias and benign osteoporosis. Clin Chem. 2001; 47(4):686-93. View

18.

Zangari M, Yaccoby S, Cavallo F, Esseltine D, Tricot G . Response to bortezomib and activation of osteoblasts in multiple myeloma. Clin Lymphoma Myeloma. 2006; 7(2):109-14. DOI: 10.3816/CLM.2006.n.047. View

19.

Farrugia A, Atkins G, To L, Pan B, Horvath N, Kostakis P . Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res. 2003; 63(17):5438-45. View

20.

Oyajobi B, Mundy G . Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma. Cancer. 2003; 97(3 Suppl):813-7. DOI: 10.1002/cncr.11133. View